{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:31Z","timestamp":1753891891283,"version":"3.41.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Wiskott\u2013Aldrich syndrome (WAS) is an X-linked genetic disorder with a variable phenotypic expression that includes thrombocytopenia, eczema, and immunodeficiency. Some patients may also exhibit autoimmune manifestations. Patients with WAS are at increased risk of developing malignancies such as lymphoma. Allogeneic hematopoietic cell transplantation remains the only curative treatment. Haploidentical bone marrow transplantation (haplo-BMT) with post-transplant cyclophosphamide (PT-CY) has more recently been applied in WAS. Here, we report two brothers who underwent successful T-cell replete haplo-BMT with PT-CY at ages 9 months and 4 years using their father as the donor. Our myeloablative regimen was well-tolerated with minimal organ toxicity and no acute or chronic graft vs. host disease (GvHD). Haplo-BMT may be considered as a safe and effective option for patients with WAS who do not have available human leukocyte antigen (HLA) matched donors.<\/jats:p>","DOI":"10.3389\/fped.2021.647505","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T04:35:57Z","timestamp":1635309357000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Haploidentical Bone Marrow Transplantation in Two Brothers With Wiskott\u2013Aldrich Syndrome Using Their Father as the Donor"],"prefix":"10.3389","volume":"9","author":[{"given":"Jasmine","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica Hass","family":"Alfonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naresh","family":"Reddivalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Angulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Katsanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/MOH.0b013e3282f30448","article-title":"Wiskott-Aldrich syndrome","volume":"15","author":"Notarangelo","year":"2008","journal-title":"Curr Opin Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbmt.2008.10.007","article-title":"Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment","volume":"15","author":"Ochs","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1182\/blood-2012-08-448118","article-title":"Characteristics and outcome of early-onset, severe forms of Wiskott-Aldrich syndrome","volume":"121","author":"Mahlaoui","year":"2013","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1182\/blood.V99.6.2268","article-title":"Missense mutations of the WASP gene cause intermittent X-linked thrombocytopenia","volume":"99","author":"Notarangelo","year":"2002","journal-title":"Blood."},{"key":"B5","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S0952-7915(03)00112-2","article-title":"Wiskott-Aldrich syndrome: a model for defective actin reorganization, cell trafficking and synapse formation","volume":"15","author":"Notarangelo","year":"2003","journal-title":"Curr Opin Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1182\/blood-2003-05-1592","article-title":"Mutations of the Wiskott-Aldrich syndrome protein (WASP): hotspots, effect on transcription, and translation and phenotype\/genotype correlation","volume":"104","author":"Jin","year":"2004","journal-title":"Blood."},{"key":"B7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/01.moh.0000168520.98990.19","article-title":"Structure and function of the Wiskott-Aldrich syndrome protein","volume":"12","author":"Ochs","year":"2005","journal-title":"Curr Opin Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1182\/blood.2019002939","article-title":"Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report","volume":"135","author":"Burroughs","year":"2020","journal-title":"Blood."},{"key":"B9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1182\/blood-2007-03-076679","article-title":"Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation","volume":"111","author":"Ozsahin","year":"2008","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3324\/haematol.2016.158808","article-title":"A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome","volume":"102","author":"Shekhovtsova","year":"2017","journal-title":"Haematologica."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood-2010-11-319376","article-title":"Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study","volume":"118","author":"Moratto","year":"2011","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-09-602573","article-title":"Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome\/X-linked thrombocytopenia","volume":"126","author":"Gerrits","year":"2015","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/j.bbmt.2020.07.003","article-title":"Outcomes after haploidentical stem cell transplantation with post-transplantation cyclophosphamide in patients with primary immunodeficiency diseases","volume":"26","author":"Fernandes","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"key":"B14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.bbmt.2016.11.016","article-title":"Nonmyeloablative haploidentical bone marrow transplantation with post-transplantation cyclophosphamide for pediatric and young adult patients with high-risk hematologic malignancies","volume":"23","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e27092","DOI":"10.1002\/pbc.27092","article-title":"Posttransplant cyclophosphamide for haploidentical stem cell transplantation in children with Wiskott-Aldrich syndrome","volume":"65","author":"Yue","year":"2018","journal-title":"Pediatr Blood Cancer."},{"key":"B16","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41409-020-01040-9","article-title":"Haploidentical stem cell transplantation with post-transplant cyclophosphamide for osteopetrosis and other nonmalignant diseases","volume":"56","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"B17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/bmt.2017.25","article-title":"Successful HLA haploidentical HSCT with post-transplant cyclophosphamide in Wiskott-Aldrich syndrome","volume":"52","author":"Kreetapirom","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s10875-019-00600-z","article-title":"Haploidentical stem cell transplantation with post-transplant cyclophosphamide for primary immune deficiency disorders in children: challenges and outcome from a tertiary care center in South India","volume":"39","author":"Uppuluri","year":"2019","journal-title":"J Clin Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1097\/MPH.0000000000001841","article-title":"Successful haploidentical stem cell transplant with posttransplant cyclophosphamide in Wiskott-Aldrich syndrome with myeloablative conditioning","volume":"43","author":"Sharma","year":"2021","journal-title":"J Pediatr Hematol Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1097\/MPH.0000000000000959","article-title":"Successful reduced intensity conditioning alternate donor stem cell transplant for Wiskott-Aldrich syndrome","volume":"39","author":"Thakkar","year":"2017","journal-title":"J Pediatr Hematol Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fped.2020.00282","article-title":"T-cell replete myeloablative haploidentical bone marrow transplantation is an effective option for pediatric and young adult patients with high-risk hematologic malignancies","volume":"8","author":"Katsanis","year":"2020","journal-title":"Front Pediatr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jha2.20","article-title":"Progressive substitution of post-transplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation","volume":"1","author":"Katsanis","year":"2020","journal-title":"eJHaem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.bbmt.2018.06.007","article-title":"Haploidentical bone marrow transplantation with post-transplant cyclophosphamide\/bendamustine in pediatric and young adult patients with hematologic malignancies","volume":"24","author":"Katsanis","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3324\/haematol.2015.138990","article-title":"Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults","volume":"101","author":"Mehta","year":"2016","journal-title":"Haematologica."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1038\/s41375-020-0850-9","article-title":"Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia","volume":"34","author":"Nagler","year":"2020","journal-title":"Leukemia."},{"key":"B27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41409-019-0499-z","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation","volume":"55","author":"Ciurea","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"B28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U","volume":"371","author":"Gragert","year":"2014","journal-title":"registry. N Engl J Med."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.647505\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T04:36:00Z","timestamp":1635309360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.647505\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":28,"alternative-id":["10.3389\/fped.2021.647505"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.647505","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"article-number":"647505"}}